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Viral infections are a common cause of asthma exacerbations, with human rhinoviruses (RV) the most common trigger. RV signals
through a number of different receptors, including toll-like receptor (TLR)3. Tenascin-C (TN-C) is an immunomodulatory
extracellular matrix protein present in high quantities in the airway of people with asthma, and expression is also upregulated in
nasal lavage fluid in response to RV infection. Respiratory viral infection has been demonstrated to induce the release of small
extracellular vesicles (sEV) such as exosomes, whilst exosomal cargo can also be modified in the bronchoalveolar lavage fluid of
people with asthma. These sEVs may potentiate airway inflammation and regulate the immune response to infection. This study
characterises the relationship between RV infection of bronchial epithelial cells and the release of TN-C, and the release of sEVs
following stimulation with the TLR3 agonist and synthetic viral mimic, poly(I:C), as well as the function of the released protein /
vesicles. The BEAS-2B airway epithelial cell line and primary human bronchial epithelial cells (PBECs) from asthmatic and
non-asthmatic donors were infected with RV or treated with poly(I:C). TN-C expression, release and localisation to sEVs was
quantified. TN-C expression was also assessed following intra-nasal challenge of C57BL/6 mice with poly(I:C). BEAS-2B cells and
macrophages were subsequently challenged with TN-C, or with sEVs generated from BEAS-2B cells pre-treated with siRNA targeted
to TN-C or control. The results revealed that poly(I:C) stimulation induced TN-C release in vivo, whilst both poly(I:C) stimulation and
RV infection promoted release in vitro, with elevated TN-C release from PBECs obtained from people with asthma. Poly(I:C) also
induced the release of TN-C-rich sEVs from BEAS-2B cells. TN-C, and sEVs from poly(I:C) challenged cells, induced cytokine synthesis in
macrophages and BEAS-2B cells, whilst sEVs from control cells did not. Moreover, sEVs with approximately 75% reduced TN-C
content did not alter the capacity of sEVs to induce inflammation. This study identifies two novel components of the inflammatory
pathway that regulates the immune response following RV infection and TLR3 stimulation, highlighting TN-C release and
pro-inflammatory sEVs in the airway as relevant to the biology of virally induced exacerbations of asthma.
  
 Contribution to the field
Human Rhinoviruses (RV) are a major cause of asthma exacerbations that, if untreated, can lead to mortality in severe cases. Due
to the large variety of RV serotypes, there is currently no available vaccine or effective therapeutics. Further research is,
therefore, required to determine the mechanisms by which these exacerbations occur, in order to reveal potential therapeutic
downstream targets of infection. The work in this study demonstrates two novel components of the inflammatory pathway
generated in response to RV, adding to the understanding of how RV-induced exacerbations of asthma may occur. These novel
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Abstract 21 
Viral infections are a common cause of asthma exacerbations, with human rhinoviruses (RV) the most 22 
common trigger. RV signals through a number of different receptors, including toll-like receptor 23 
(TLR)3. Tenascin-C (TN-C) is an immunomodulatory extracellular matrix protein present in high 24 
quantities in the airway of people with asthma, and expression is also upregulated in nasal lavage fluid 25 
in response to RV infection. Respiratory viral infection has been demonstrated to induce the release of 26 
small extracellular vesicles (sEV) such as exosomes, whilst exosomal cargo can also be modified in 27 
the bronchoalveolar lavage fluid of people with asthma. Interestingly Tthese sEVs may potentiate 28 
airway inflammation and regulate the immune response to infection. This study characterises the 29 
relationship  between RV infection of bronchial epithelial cells and the release of TN-C, and the release 30 
of sEVs following stimulation with the TLR3 agonist and synthetic viral mimic, poly(I:C), as well as 31 
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the function of the released protein / vesicles. The BEAS-2B airway epithelial cell line and primary 32 
human bronchial epithelial cells (PBECs) from asthmatic and non-asthmatic donors, were infected with 33 
RV or treated with the synthetic viral mimic, poly(I:C). TN-C expression, release and localisation to 34 
sEVs was quantified. TN-C expression was also assessed following intra-nasal challenge of C57BL/6 35 
mice with poly(I:C). BEAS-2B cells and macrophages were subsequently challenged with TN-C, or 36 
with sEVs generated from PBECs BEAS-2B cells pre-treated with siRNA targeted to TN-C or control. 37 
The results revealed that poly(I:C) stimulation induced TN-C release in vivo, whilst both poly(I:C) 38 
stimulation and RV infection promoted  release in vitro, with elevated TN-C release from PBECs 39 
obtained from people with asthma. Poly(I:C) also induced the release of TN-C- rich sEVs from BEAS-40 
2B cells. Purified TN-C, and sEVs from poly(I:C) challenged cells, induced cytokine synthesis in 41 
macrophages and BEAS-2B cells, whilst sEVs from control cells did not. Moreover, sEVs with 42 
approximately 7560% reduced TN-C content did not alter the capacity of sEVs to induce inflammation. 43 
This study identifies two novel components of the inflammatory pathway that regulates the immune 44 
response following RV infection and TLR3 stimulation, highlighting TN-C release and elevated pro-45 
inflammatory sEVs in the airway as relevant to the biology of virally induced exacerbations of asthma. 46 
Abbreviations 47 
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Word Count: 36974527 63 
1. Introduction 64 
Asthma is a chronic disease characterised by airway inflammation, remodelling, and airway 65 
hyperresponsiveness (AHR) (1). Around 5-10% of those with the disease have severe asthma with 66 
poorly controlled symptoms (2), and exacerbations are an acute, frequently occurring, and potentially 67 
severe manifestation of this illness (3). One of the main causes of asthma exacerbations are respiratory 68 
viruses, with the most common viruses responsible being human rhinoviruses (RV) (4). 69 
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RV are single-stranded RNA, non-enveloped viruses, which are members of the Picornaviridae family 70 
and encompass around 160 serotypes. These viruses are classified either by the A-B-C classification 71 
system (based on the similarity in the RNA sequences of the viral protein 1), whereas the major-minor-72 
C classification system is based on the entry receptor used by the virus to enter the cell (5-7). Major 73 
serotypes bind to intracellular adhesion molecule 1 (ICAM-1) on the cell surface, minor serotypes use 74 
various low density lipoprotein receptors (LDLRs) (6) and RV-C was identified in 2006 and uses 75 
cadherin-related family member 3 (CDHR3) for binding and replication (7).  76 
Bronchial epithelial cells are the principle site of RV binding and replication, and RV are recognised 77 
by pattern recognition receptors (PRRs) including toll-like receptors (TLR)2 and TLR3, and the 78 
Retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) melanoma differentiation-associated-79 
protein 5 (MDA5) and retinoic acid-inducible gene (RIG-I) (8, 9). TLR and RLR activation induces 80 
interferon regulatory factor (IRF), mitogen-activated protein kinase (MAPK) and NF-κB signalling, 81 
leading to cytokine and interferon production (10, 11). Whilst this inflammation is typically readily 82 
resolved, RV infection can lead to an over-exaggerated response in people with asthma, resulting in 83 
excessive cytokine release and mucus hypersecretion that are characteristic of asthma exacerbations 84 
(12). 85 
RV can promote the deposition of extracellular matrix (ECM) proteins, with tenascin-C (TN-C) mRNA 86 
expression enhanced in nasal cells following infection (13). TN-C is composed of four main domains: 87 
the tenascin assembly (TA) domain, epidermal growth factor (EGF)-like repeats, fibronectin type III 88 
(FNIII)-like repeats and fibrinogen globe-like (FBG-C) domain (14). It can range in size from 180-330 89 
kDa, and expression is low in the healthy adult airway, but is increased in the basement membrane of 90 
people with asthma (15). TN-C expression correlates with asthma severity in humans (15), AHR in 91 
mouse models of asthma is reduced in TN-C KO mice (16), and a single nucleotide polymorphism 92 
(SNP) in the structure of TN-C associates with adult bronchial asthma (17). TN-C is a key driver of 93 
chronic inflammation in a number of different pathologies (summarised in (18)) through both FBG-C-94 
TLR4 and FNIII-integrin interactions. This is well established in models of rheumatoid arthritis (RA), 95 
with the FBG-C domain interacting with TLR4 receptors on the surface of synovial fibroblasts and 96 
macrophages (14, 19). However, despite evident roles for TN-C in asthma biology, the expression of 97 
TN-C in bronchial epithelial cells and the role of TN-C in RV-induced inflammation have not been 98 
studied. 99 
In this study we investigated bronchial epithelial cell TN-C expression and release following RV 100 
infection, and determined the function of the protein. We observed release of TN-C upon infection, 101 
and established that purified recombinant FBG-C had the ability to induce inflammatory cytokine 102 
release in bronchial epithelial cells and macrophages. Surprisingly, a large proportion of TN-C was 103 
associated with small extracellular vesicles (sEV), which have previously been implicated in asthmatic 104 
airway inflammation, and viral challenge increased the concentration of overall sEV release. sEVs 105 
from virally stimulated cells had the ability to induce inflammatory and antiviral cytokine production 106 
in bronchial epithelial cells, whilst sEVs from control cells did not. Finally, sEV induced inflammation 107 
was determined to be independent of TN-C. Thus, this study identifies TN-C and sEVs as two novel 108 
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drivers of the airway inflammation that underpins asthma pathogenesis, and therefore may be potential 109 
future therapeutic targets to help control RV-induced asthma exacerbations. 110 
2. Materials and Methods 111 
Viral culture 112 
RV minor serotype 1B (RV-1B) and major serotype 16 (RV-16) were obtained from ATCC (LGC 113 
Standards, Teddington, UK) and viral stocks generated by infecting HeLa Ohio cells (ATTC) as 114 
previously described (20). The cytopathic effect was then determined and the multiplicity of infection 115 
(MOI) calculated. 116 
Cell culture 117 
The BEAS-2B epithelial cell line, and primary bronchial epithelial cells (PBECs) isolated from healthy 118 
humans, were purchased from ATCC and Promocell (Heidelberg, Germany) and cells were maintained 119 
as described (21, 22). PBECs were also obtained during bronchoscopy from adult (18-55 years old) 120 
non-atopic non-asthmatic controls (NANA) and patients with atopic asthma (AA) (23), with written 121 
informed consent, in accordance with the Declaration of Helsinki and a protocol approved by London 122 
Bridge Research Ethics committee (reference number 12/LO/1278), and maintained in the same way 123 
as the purchased cells. The AA subjects had a prior clinical diagnosis of asthma, scored > 0.75 on an 124 
asthma control questionnaire, had a histamine PC20 of less than 8 μg/ml, and atopy was confirmed by 125 
a positive skin prick test to timothy grass pollen (in a panel of 10 aeroallergens) [23]. NANA subjects 126 
had a histamine PC20 of greater than 8 μg/ml (23).  Peripheral blood mononuclear cells (PBMCs) were 127 
isolated from peripheral venous blood of healthy volunteers (21), with written informed consent, in 128 
accordance with a protocol approved by South Sheffield Local Research Ethics Committee (reference 129 
number: 05/Q2305/4) and differentiated into monocyte-derived macrophages using a previously 130 
established method (14). 131 
Cell stimulation and infection 132 
Cells were seeded in 6, 12 or 96 well plates, grown to confluency (80%) and placed in supplement free 133 
media overnight. For stimulation experiments, cells were stimulated with 25 μg/ml 134 
polyinosinic:polycytidylic acid (poly([I:C]) (Invitrogen, Paisley, UK), 10 μg/ml gardiquimod 135 
(Invitrogen) or 100 ng/ml or lipopolysaccharide (LPS) serotype 0111:B4 (Sigma-Aldrich) or EH100 136 
(Enzo, Exeter, UK). For infection experiments, BEAS-2B cells or PBECs were infected with RV-1B 137 
and RV-16 (ATCC) for the indicated times at optimised MOIs (10). For TN-C stimulation experiments, 138 
recombinant FBG-C protein was expressed and purified as described (14, 24), before being added to 139 
cells at the indicated concentrations for 24 hours. For small extracellular vesicle (sEV) stimulation 140 
experiments, isolated sEVs (see supplemental methods) were added to at the indicated concentrations 141 
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Murine model 145 
This study was carried out in accordance with the principles of the Basel Declaration and 146 
recommendations of Animal (Scientific Procedures) Act 1986, United Kingdom Home Office. The 147 
protocol was approved by the animal welfare and ethical review body at the University of Sheffield, 148 
and work was carried out under project license code 40/3726 and establishment license code 50/2509. 149 
Under 4% isofluorane (Abbott Laboratories Illinois, USA), C57BL/6 adult mice (see supplemental 150 
methods for more information) were intranasally stimulated with 50 μl PBS (Oxoid, ThermoFisher, 151 
Basingstoke, UK) or 50 μl PBS containing 100 μg poly(I:C). The mice were sacrificed and 152 
bronchoalveolar lavage fluid (BALF) collected as previously described (25).  153 
Western blot 154 
Where required, cell lysates were prepared as previously established (21). For supernatant samples, 155 
4xSDS loading buffer was added and samples were analysed following the same protocol. Cell-lysate 156 
western blot samples were probed for human TN-C (N-Terminal, mab1908, Merck Millipore, 157 
California, USA), Histidine-Tag (H1029, Sigma-Aldrich) and β-actin (A5316, Sigma-Aldrich), with 158 
TN-C expression normalised to β-actin, whilst supernatant samples were analysed for TN-C only. 159 
Mouse BALF was concentrated by trichloroacetic acid (TCA; Sigma-Aldrich) precipitation prior to 160 
analysis and TN-C expression determined using mouse TN-C antibody (N-Terminal, T3413, Sigma-161 
Aldrich). sEV isolates were analysed for sEV-enriched proteins cluster of differentiation 9 (CD9; sc-162 
13118; Santa-Cruz Biotechnology, Dallas, USA) and flotillin-1 (ab13493; Abcam, Cambridge, UK), 163 
with the negative control glucose regulated protein 94 (GRP94; ab7291; Abcam) utilised to confirm 164 
the lack of cellular protein contamination. Densitometrical analysis was performed using ImageJ 165 
software (Version 1.5i; NIH). Due to multiple variants of TN-C being expressed, the dominantly 166 
expressed band was measured for each experiment.  167 
ELISA  168 
Cell-free supernatants were collected and quantified for C-X-C Motif Ligand 8 (CXCL8), CCL5 and 169 
IL-5 (R&D, Minneapolis, USA) and TN-C N-Terminal Kit (Cloud Corp, Texas, USA) using matched 170 
Ab pairs by enzyme-linked immunosorbent assay (ELISA), following the manufacturer’s instructions. 171 
Minimum detection levels (all pg/ml) were CXCL8: 78.125, TN-C: 125, IL-5: 156.25 and CCL5: 172 
156.25. 173 
MTT assay 174 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) assay assessed 175 
nicotinamide adenine dinucleotide phosphate (NADPH) activity as a measure of cell metabolic activity 176 
and thus viability, and was performed as previously described (26). 177 
 178 
 179 
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Nanoparticle tracking analysis 180 
The size and concentration of the isolated EVs were analysed by the ZetaView® Nanoparticle Tracking 181 
Analyser (Particle Metrix, Dusseldorf, Germany). Each sample was diluted in filtered PBS (1:30-1:50) 182 
to reach the optimum detection limit in the machine and measured 3 times. 183 
Statistics 184 
Data were analysed and presented via GraphPad Prism v7.0 (California, USA) as mean ± SEM of at 185 
least three independent experiments, with each replicate carried out on a separate BEAS-2B cell 186 
passage or, independent PBEC donor,. please see figure legends for specific experimental replicate 187 
numbers.  Statistical tests performed are also detailed within the figure legends with significant 188 
differences indicated by *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001. 189 
3. Results  190 
RV infection induces TN-C release in vitro in PBECs, with release greater in PBECs obtained 191 
from people with asthma, whilst the viral mimic poly(I:C) induces TN-C release into the murine 192 
airway. 193 
TN-C is a protein that, once released, can have a pro-inflammatory function upon interaction with cells 194 
such as macrophages (14). Therefore, we first investigated whether epithelial cell TN-C release 195 
occurred in response to RV. PBECs from NANA (healthy non-atopic non-asthmatic control) and AA 196 
(atopic asthmatic) adult patients were obtained and infected with RV-1B (a minor group RV) and RV-197 
16 (a major group RV) in vitro. Western blotting of cell culture supernatant revealed increased TN-C 198 
release upon infection with both RV serotypes. When analysed by densitometry and normalised to total 199 
protein concentration (determined by bicinchoninic acid assay), RV-16 infection produced greater TN-200 
C release in AA PBECs compared to the AA media control and to the NANA RV-16 treated samples 201 
(Figure 1A and 1B). Due to previous evidence of TN-C KO mice having reduced AHR severity (16), 202 
the relationship between poly(I:C) (a TLR3 agonist and viral mimic) stimulation and TN-C release in 203 
an in vivo murine model was also investigated. C57BL/6 mice were stimulated intranasally with 204 
poly(I:C), using PBS as a vehicle control, sacrificed at the indicated times, and BALF collected. 205 
Western blotting BALF revealed TN-C levels were increased 48 hours post poly(I:C) stimulation, 206 
compared to the PBS treated controls (Figure 1C and 1D). 207 
TN-C expression and release in bronchial epithelial cells is triggered by TLR3, but not TLR7, 208 
activation 209 
TN-C release in response to RV infection of human bronchial epithelial cells in vitro has not, to our 210 
knowledge, been previously determined. Thus we further investigated this pathway, as well as 211 
examining the TLRs responsible. TN-C mRNA levels, and protein expression and release, in response 212 
to RV, poly(I:C) and gardiquimod (a TLR7 agonist) in the BEAS-2B cell line and PBECs from healthy 213 
donors was determined, with TNFα used as a positive control. TN-C mRNA expression was analysed 214 
by qPCR and normalised to GAPDH expression. Cell-associated TN-C expression and TN-C release 215 
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was assessed by western blotting cell lysates and cell supernatant respectively, and normalised to β-216 
actin (lysates only). TN-C levels in cell supernatants were further quantified by ELISA. 217 
TN-C release in PBECs in response to RV-1B (Figure 2A) and RV-16 (Figure 2B) infection was 218 
confirmed by TN-C ELISA, with peak TN-C release occurring at 48-72 hours post infection. PBECs 219 
also released TN-C upon stimulation with poly(I:C) (Figure 2C), and we confirmed that as expected. 220 
poly(I:C) induced the release of CXCL8 (Figure Supplemental [S]1A and 1C) and CCL5 (Figure S1B 221 
and 1D) from. both BEAS-2B and PBECs. To confirm the specificity of the TN-C antibody, 222 
recombinant TN-C with a histidine-tag was purified, and compared to PBEC intracellular associated 223 
TN-C by western blot. The purified TN-C displayed the same band pattern as the more complex, 224 
cellular samples, (Figure S1E). , PBECs  did not respond to gardiquimod stimulation (as measured by 225 
CXCL8; Figure S2A) and TN-C release did not occur (measured by western blot; Figure S21B). 226 
Gardiquimod activity was confirmed by stimulation of macrophages (Figure S21A). Poly(I:C) and RV-227 
1B treatment of BEAS-2B cells also resulted in TN-C release (Figure 2D), with no response to 228 
gardiquimod (data not shown). Together these data demonstrate TN-C release is not RV serotype 229 
specific and can be promoted by TLR3, but not TLR7 activation in primary human epithelial cells and 230 
cell lines.   231 
Upregulation of TN-C mRNA and cell-associated TN-C protein was not observed in PBECs in 232 
response to poly(I:C), RV-1B or RV-16 (data not shown), whilst poly(I:C) stimulated TN-C mRNA 233 
expression in BEAS-2B cells at 24 hours (Figure S21C), and cell-associated TN-C protein expression 234 
at 24 and 48 hours post stimulation (Figure S21D), with levels of expression similar to that induced by 235 
TNFα. Basal levels of TN-C mRNA expression (Figure S21E) and cell-associated protein (Figure 236 
S21F) were significantly greater in PBECs compared to BEAS-2B cells. Together these data show a 237 
cell-type specific effect of viral infection / poly(I:C) stimulation on TN-C expression, and suggests that 238 
the required rate of TN-C transcription needed to facilitate protein release depends on existing 239 
intracellular expression.  240 
TN-C release does not occur as a result of cell death 241 
The next aim was to investigate the mechanism of TN-C release following viral infection. RV infection 242 
of bronchial epithelial cells can promote the induction of apoptosis (27), and it was important to 243 
ascertain whether the observed TN-C release is directly promoted by infection or an indirect by-product 244 
of RV-induced cytotoxicity.  245 
PBECs were infected with RV, stimulated with poly(I:C),  or treated with staurosporine (a promoter 246 
of apoptosis) for up to 72 hours, and the MTT cell metabolic activity assay performed. Supernatants 247 
were collected and TN-C levels were compared by western blot. RV infection resulted in a significant 248 
reduction in cell metabolic activity (approximately 30%; Figure 3A) whilst staurosporine treatment 249 
caused approximately 70-80% loss reduction (Figure 3A and 3B) compared to the media control. In 250 
contrast,, poly(I:C) did not affect cell metabolic activity. Importantly, RV infection (Figure 3C and 3E) 251 
and poly(I:C) stimulation (Figure 3D and 3F) both induced TN-C release from PBECs, whilst 252 
staurosporine treatment did not (Figure 3C-3F). This indicates that virally induced TN-C release is not 253 
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associated with significant changes in cell viability and that induction of epithelial cell death is not 254 
sufficient to induce TN-C release.  255 
Poly(I:C) stimulation of BEAS-2B cells induces sEV-associated TN-C release 256 
sEVs are a type of extracellular vesicle (EV) that range from 50-200 nm in size and originate from the 257 
endosomal pathway or the plasma membrane (28, 29). sEVs can encompass exosomes and smaller 258 
microvesicles, and were investigated as a potential mechanism of TN-C release as TN-C association 259 
with these vesicles has previously been reported in cancerous colorectal cell lines (29) and sEVs have 260 
been implicated in asthma pathogenesis and airway inflammation (30). There is a need for large 261 
amounts of sEVs to be isolated for accurate NTA analysis and sEVs also have a short storage time 262 
before degradation, thus, BEAS-2B cells were chosen as suitable cells, due to their quicker doubling 263 
time and greater density in culture than PBECs. 264 
BEAS-2B cells were cultured in EV-depleted media, stimulated with poly(I:C) and supernatant 265 
collected for sEV isolation, using a four-step ultracentrifugation method (Figure S32A). The sEVs 266 
were characterised by western blotting, confirming the presence of sEV enriched-proteins CD9 and 267 
flotillin-1, and the absence of intracellular protein control GRP94 in the sEV samples (Figure 4A). The 268 
average sEV size, as determined by NTA, was 100 nm and the concentration of sEVs increased at 72 269 
hours post stimulation (Figure 4B). sEV associated TN-C expression was measured by western blot, 270 
and increased at 72 hours post-stimulation (Figure 4C and 4D). Analysis of the amount of TN-C left 271 
in the supernatant after sEV isolation demonstrated that approximately 50% of released TN-C is 272 
associated with sEVs (Figure S32B). Together these data reveal that TN-C release occurs in two 273 
formats; soluble TN-C protein in the cell supernatant and TN-C protein associated with sEVs. 274 
FBG-C and poly(I:C)-induced sEVs induce cytokine release in BEAS-2B cells, but the sEV-275 
pathway may not be TN-C-dependent 276 
This work has demonstrated that RV infection induces the release of soluble TN-C from bronchial 277 
epithelial cells, and that TN-C is also associated with poly(I:C)-induced sEV release. As the 278 
inflammatory function of TN-C on epithelial cells has not been investigated, we measured the effect 279 
of soluble FBG-C on BEAS-2B cells, using macrophages as a control cell type. RV infection has also 280 
been hypothesised to induce changes in the sEV miRNA composition, potentially contributing to 281 
enhanced airway inflammation and anti-viral activity (31), whilst sEVs from nasal lavage fluid of 282 
people with chronic airway inflammation contain altered protein cargo (32). The inflammatory and 283 
anti-viral consequence of sEV addition to BEAS-2B cells was therefore investigated, and the role of 284 
TN-C in this pathway determined.  285 
FBG-C was purified by Ni2+ purification as per (14, 24) and characterised for activity and structure 286 
(Figure S4A-C3). A concentration response curve was generated in BEAS-2B cells, with 1-2µM FBG-287 
C determined to be sufficient to induce CXCL8 release (Figure S34D). MDMs were also stimulated 288 
with 1µM FBG-C, with previous work in our group demonstrating that concentrations between 0.05-289 
1µM were sufficient to induce an inflammatory response [14, 24].  FBG-C was added exogenously to 290 
macrophages (with an LPS TLR4 positive control) or BEAS-2B cells, cell-free supernatants were 291 
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collected, and CXCL8 release analysed by ELISA. FBG-C stimulation resulted in substantial CXCL8 292 
release in macrophages, with the amount released similar to that elicited by LPS stimulation (Figure 293 
5A). Due to contradictory evidence about the ability of bronchial epithelial cells to respond to LPS 294 
(and thus respond to TLR4 agonists) (20), BEAS-2B cells were first stimulated with rough LPS 295 
serotype EH100 and smooth LPS serotype 0111:B4 and CXCL8 production measured. Smooth LPS, 296 
but not rough LPS induced significant cytokine release from BEAS-2B cells (Figure 5B); whilst TN-297 
C-FBG stimulation (1 µM) also elicited CXCL8 release in BEAS-2B cells (Figure 5C).  298 
BEAS-2B cells were next stimulated with poly(I:C) for 72 hours and sEVs were isolated as per Figure 299 
S32A. sEVs were quantified by NTA and added to BEAS-2B cells at 10,000-20,000 sEVs per µl for 300 
24 hours, before cell free supernatants were collected for analysis. Addition of unstimulated media 301 
control sEVs did not induce any cytokine release from BEAS-2B cells, whilst addition of sEVs from 302 
poly(I:C) stimulated cells induced CXCL8 (Figure 5D), IL-6 (Figure 5E) and CCL5 (Figure 5F) 303 
release. A zero hour control was used in the CXCL8 experiment, with sEVs isolated instantly after 304 
poly(I:C) stimulation. No CXCL8 release was induced, demonstrating a lack of poly(I:C) 305 
contamination. To determine what role TN-C played in this response, the experiment was repeated 306 
with a 100 nM TN-C siRNA or 100 nM control siRNA pre-treatment step prior to poly(I:C) 307 
stimulation. Despite a knockdown efficiency of approximately 765% (Figure S43D and S43E), there 308 
was no difference in poly(I:C) induced CXCL8 (Figure 5G) or CCL5 (Figure 5H) release between the 309 
two siRNA groups. 310 
4. Discussion 311 
This study identifies two novel pathways that can mediate inflammation in bronchial epithelial cells 312 
and macrophages:  the release of the ECM protein TN-C in response to RV infection (which is elevated 313 
in PBECs from people from asthma) elicited , and the generation and release of sEVs in response to 314 
TLR3 stimulation by poly(I:C).  315 
The proposed mechanisms of RV-dependent TN-C release and poly(I:C)-dependent sEV release are 316 
summarised in Figure 6. Work in this study determined that TN-C release in bronchial epithelial cells 317 
is triggered by TLR3, but not TLR7 signalling, with the lack of response to gardiquimod correlating 318 
with previous work from our lab (21). TN-C release occurred in response to both minor and major RV 319 
serotypes. In contrast, intracellular TN-C was not upregulated in response to RV in PBECs, results 320 
which are in keeping with another study, which demonstrated RV infection of primary airway smooth 321 
muscle cells did not promote expression of TN-C (33). The amount of RV-dependent TN-C 322 
upregulation may depend on basal levels of expression. We theorise that the lack of significant 323 
intracellular upregulation of TN-C in PBECs following infection was due to the high basal levels that 324 
are present in the cells, and therefore promotion of TN-C expression was not required in order for the 325 
protein to be released. This also explains why upregulation was observed in BEAS-2B cells upon 326 
stimulation and infection, as these cells express low basal levels of TN-C. As TNFα and TGFβ are 327 
known transcriptional regulators of TN-C (34, 35), and are produced in response to RV infection (36), 328 
we postulate these cytokines trigger the signalling cascades that promote the release of TN-C from 329 
bronchial epithelial cells. This pathway was also confirmed in vivo, with nasal administration of 330 
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poly(I:C) inducing TN-C release in BALF from mice at 48 hours post stimulation. Poly(I:C) was 331 
chosen as a relevant stimulus as this model has previously been shown to elicit lung inflammation and 332 
impair lung function in mice in a TLR3 dependent manner (Stowell et al., 2009). We confirmed that 333 
poly(I:C) produced a robust immune response 48 hours post stimulation (data not shown). 334 
Once released into surrounding environment, soluble TN-C has the ability to induce TLR4 335 
inflammation through the FBG-C domain. BEAS-2B cells in culture have the ability to respond to 336 
smooth LPS but not rough LPS, (which can be overcome by co-culture with monocytes, which provide 337 
the required co-receptors (20)) and our work now reveals that FBG-C can also induce inflammatory 338 
cytokine release from bronchial epithelial cells. This draws a parallel with, and builds on, our previous 339 
work demonstrating the ability of TN-C to induce inflammatory cytokine release via FBG-C-TLR4 340 
interactions in macrophages and fibroblasts (14). Work in the future will aim to detail exactly how 341 
much TN-C is released in the airway following infection, both from AA and NANA samples.  342 
RV infection lasts on average 9-11 days, meaning multiple rounds of infection, viral egress and 343 
reinfection occurs (37). Evidence is contradictory about whether asthma suffers are more susceptible 344 
to RV infection, however it is clear that RV infection persists longer in people with asthma and they 345 
have more severe symptoms (37). The isoforms of TN-C released in response to RV are large (>250 346 
kDa), which are more resistant to matrix metalloproteinase 9 (MMP9) degradation (38) and have a 347 
greater capacity to induce inflammation than smaller isoforms (14, 39). In people with asthma, the 348 
exaggerated response to RV infection, leading to greater TN-C release, could lead to TN-C persisting 349 
in the airway after the clearance of viral infection, incorporating into the ECM and exerting its 350 
inflammatory effect locally (15).  351 
Furthermore, the release of TN-C could form a positive feedback loop (previously demonstrated in 352 
RA), further increasing expression and release of the protein (40). Also, viral infection itself may result 353 
in a greater susceptibility to virally induced-TN-C release and the consequential TLR4 dependent 354 
inflammation, with respiratory syncytial virus (RSV) having been previously shown to induce the 355 
upregulation of TLR4 in bronchial epithelial cells (41). 356 
The work described here also established that poly(I:C) stimulation RV infection of BEAS-2B cells 357 
induced sEV release and provided novel information that TN-C is associated with these vesicles. 358 
Results from this study demonstrate that approximately 50% of the released TN-C was associated with 359 
sEVs, whilst the other 50% was present in the supernatant. Although our work determined that TN-C 360 
does not play a role in sEV-induced inflammation, tThis study still establishes sEVs as an inflammatory 361 
pathway of importance in the airway, with initial results indicating that sEVs exert an inflammatory 362 
effect in a TN-C-independent manner. However, as 100% of TN-C knockdown was not achieved, 363 
further investigation is required in order to discount TN-C from having a role in TLR3-induced sEV-364 
dependent inflammation. The se results in this manuscripts are also consistent with a recent study that 365 
demonstrated that RSV-induced sEVs promote inflammatory cytokine release in an alveolar epithelial 366 
cell line through IP-10, CCL2 and CXCL10 release (42). Our work also highlights for the first time 367 
that virally-stimulated sEVs promote an anti-viral CCL5 response in surrounding bronchial epithelial 368 
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cells after infection. sEVs can also ‘travel’ quite large distances of at least several cell diameters (43), 369 
and thus will induce a more widespread immune response to RV infection than soluble TN-C.  370 
The revelation that RV infection and poly(I:C) stimulation can induce inflammatory TN-C and /or sEV 371 
release is of importance in the context of virally-induced asthma exacerbations. TN-C release was 372 
increased in the PBECs of AA subjects in response to RV, potentially providing evidence of a 373 
mechanism for the increased expression of the protein in the basement membrane of people with 374 
asthma (13, 15). As detailed above, RV infections persists longer in people with asthma (37) and. this, 375 
alongside increased basal cell-associated expression of TN-C in people with asthma (15), may result 376 
in the greater release of the protein upon infection, promoting a chronic inflammatory response and 377 
contributing towards the development of AHR. Furthermore, sEVs isolated from the BALF of people 378 
with asthma have an increased inflammatory miRNA profile which can contribute towards 379 
pathogenesis (44), and thus RV infection may shift the imbalance of sEV miRNA profile even further. 380 
Now the novel mechanisms of RV-induced TN-C release and poly(I:C) induced sEV release have been 381 
established, it will be paramount in the future to further characterize these pathways. We aim to 382 
investigate whether RV induces sEVs with a similar inflammatory phenotype to poly(I:C), and whether 383 
this is potentiated further in people with asthma. TN-C is a protein that can be targeted therapeutically 384 
with monoclonal antibodies that target the TLR4 binding epitope on the FBG-C domain, reducing 385 
cytokine release in RA synovial cells (19). Thus, TN-C may be a potential therapeutic target in the 386 
future in order to reduce a local inflammatory response to TN-C following RV-dependent release. 387 
Furthermore, sEVs are currently used as biomarkers in cancers such as colorectal cancer (45), and as 388 
more work unveils the role of sEVs in asthma, these vesicles, and the levels of associated TN-C, should 389 
be considered as a potential biomarker for disease severity. 390 
The data presented in this study reveals novel consequences of RV infection and poly(I:C) stimulation 391 
of bronchial epithelial cells: the induction of pro-inflammatory TN-C release that can activate local 392 
cytokine synthesis in the airway, and the release of sEVs (that contain TN-C) which have the ability to 393 
induce an immune response over longer distances. The pathway of TN-C release is also more active in 394 
the airway of people with asthma and thus identifies TN-C and sEVs as relevant to the biology of 395 
virally induced exacerbations of asthma.  396 
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 572 Figure 2. RV induced TN-C release from bronchial epithelial cells is triggered by TLR3 
activation and is not RV-serotype specific 
PBECs (A-C) and BEAS-2B cells (D) were treated with poly(I:C) (25 µg/ml), RV-1B (MOI 0.6) or 
RV-16 (MOI 1.5) for the indicated times. Cell-free supernatants were analysed by ELISA to 
measure TN-C release. Data shown are mean ± SEM (N=3-5) with each replicate a separate BEAS-
Figure 1. RV infection induces TN-C release in vitro and poly(I:C) induces TN-C  in vivo, with 
increased release observed in bronchial epithelial cells from people with asthma 
(A & B) Cell-free supernatants from NANA and AA PBECs, infected with RV-1B and RV-16 for 
6 or 24 hours, were obtained from the ALLIANCE study. (A) Cell-free supernatants were analysed 
by western blot using antibodies specific to TN-C (one representative blot shown), with media 
samples (M), RV-1B (1B) and RV-16 samples (16). (B) Densitometry of the large >250 kDa variant 
was performed in ImageJ and normalised to protein concentration (determined by a bicinchoninic 
acid assay). Data shown are mean ± SEM with each replicate carried out using an independent PBEC 
donor (n=4). (C & D) Under recovery anaesthesia, adult C57BL/6 mice were treated intranasally 
with 50 µl PBS or 100 µg poly(I:C) in 50 µl PBS for up to 48 hours. The mice were then sacrificed, 
and BALF was collected by washing the lungs with 3 ml of PBS. (C) 150 µl of mouse BALF was 
TCA precipitated to a final volume of 20 µl and the presence of TN-C at 24 and 48 hours was 
analysed by western blot (48 hour blot shown). (D) Densitometry of the small ~250 kDa variant was 
then performed using ImageJ software and normalised to neutrophil cell count. Data shown are 
mean ± SEM from a single experiment, with each point a separate mouse (3 mice for PBS treatment 
and 7 mice for poly(I:C) treatment). Significant differences in TN-C secretion are indicated by # 
p<0.05; ** p<0.01; *** p<0.001; analysed by two way ANOVA with Tukey's post-hoc test. 
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Figure 3. Induction of epithelial cell death is not sufficient to induce PBEC TN-C release  
PBECs were grown to confluence and infected with RV-1B (MOI 0.6) or stimulated with poly(I:C) 
(25 µg/ml) or staurosporine (5 µg/ml) for the indicated times. Metabolic activity was measured by 
MTT assay in response to RV and staurosporine (A). and poly(I:C) and staurosporine (B). The 
presence of TN-C was analysed by western blot (M for Media, R for RV-1B, P for poly(I:C) and S 
for staurosporine; one representative blot shown; (C and B). Densitometry of the large >250 kDa 
variant in response to RV (E) and poly(I:C) (F) was performed in ImageJ software. Values are 
expressed as mean ± SEM (N=3-4) with each replicate representing an independent PBEC donor. 
Significant differences in cell viability (# compared to media control and * compared to 
poly(I:C)/RV) and TN-C release are indicated by, * p<0.05; ** p<0.01; **** p<0.0001, analysed 
by two way ANOVA with Dunnett’s post hoc test. Analysis for MTT assay was performed on raw 
values. 
Figure 4. Poly(I:C) stimulation of BEAS-2B cells induces the release of sEVs and sEV-
associated TN-C expression 
BEAS-2B cells were grown to confluence in EV-depleted media and stimulated with poly(I:C) (25 
μg/ml) for the indicated times. sEVs were then isolated by the four spin ultracentrifugation method 
and re-suspended in 100 μl PBS. (A) CD9, flotillin-1 and GRP-94 expression was measured by 
western blot (one representative blot shown). (B) sEV concentration and size was quantified by 
Nanoparticle Tracking Analysis on ZetaView. (C) TN-C expression was measured by western blot 
(one representative blot shown) and (D) TN-C expression was quantified by densitometry using 
ImageJ software. Values are expressed as mean ± SEM (N=7) with each replicate a different cell 
passage. Significant differences in sEV release and sEV-associated protein expression are indicated 
by * p<0.05, analysed by Mann-Whitney U test (B) or two way ANOVA with Tukey’s post-hoc 
test (D). 
Figure 5. FBG-C induces cytokine release in macrophages and BEAS-2B cells and sEVs 
isolated from virally-stimulated BEAS-2B cells induce BEAS-2B cell cytokine release which 
may be independently of from TN-C  
(A) Monocyte derived macrophages were left unstimulated or stimulated with purified recombinant 
FBG-C (1 µM) or LPS smooth (S) serotype 0111:B4 (10 µg/ml) for 24 hours. (B) BEAS-2B cells 
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Figure 6. The proposed mechanism of TN-C release following RV infection of 
bronchial epithelial cells  
Upon viral infection, RV is internalised to the early endosome and uncoats. The single 
stranded RNA exits the endosome (early or late endosome depending on the RV serotype) 
and forms a temporary double stranded RNA intermediate (recognised by TLR3 in the 
cytoplasm). It is not yet clear how the endosomal TLR recognises the cytoplasmic RNA. 
Poly(I:C) enters the endosome upon addition to cells and stimulates the TLR3 pathway. 
The amount of RV/Poly(I:C)-dependent cell associated TN-C upregulation may depend 
on existing basal levels of expression in the cell, with PBECs expressing higher TN-C 
levels at baseline compared to BEAS-2B cells. Furthermore, RV-induced TN-C release 
occurs in response to major and minor serotypes of RV, and is not an indirect 
consequence of cell cytotoxicity, as poly(I:C) induces TN-C release despite no significant 
cell death. Activation of the TLR3 dependent pathway (and other pathways upon viral 
infection) induce the release of TNFα and TGFβ, known transcriptional regulators of TN-
C through the MAPK/ERK and NF-κB/p65 pathways. It is postulated that this triggers 
the signalling cascade required for the expression and release of TN-C in PBECs. Black 
lines denote events determined by experiments with both poly(I:C) and RV, the dashed 
line indicates events that occur in RV infection and the dotted line indicates events 
determined by experiments with poly(I:C) only. 
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